BYSI News and Press, BeyondSpring Inc. From 06/07/21

- Data demonstrate that combination of plinabulin and pegfilgrastim offers superior benefit for reducing the incidence and severity of febrile neutropenia (FN) and hospitalization, with better quality-of-life (QoL), compared to pegfilgrastim alone NEW YORK, June 07, 2021 (GLOBE NE...

The following slide deck was published by BeyondSpring Inc. in conjunction with this event. For further details see: BeyondSpring (BYSI) Investor Presentation - Slideshow

The first patient has been dosed in BeyondSpring's (BYSI) Phase 1b/2 investigator-initiated trial, studying the safety and tolerability of plinabulin, in triple combination therapy with both PD-1/PD-L1 antibody (mAb) and radiation therapy ((RT)).This triple combination is actively recruiting ...

Resistance to immunotherapy is a severe unmet medical need that plinabulin aims to address in combination with checkpoint inhibitors and radiotherapy First patient who failed Keytruda and chemotherapy has been dosed with plinabulin, Keytruda and radiation combination in non-smal...

Under priority review, the FDA has accepted for filing BeyondSpring's (BYSI) New Drug Application ((NDA)) seeking approval for use of plinabulin in combination with granulocyte colony-stimulating factor (G-CSF) for the prevention of chemotherapy-induced neutropenia ((CIN)). The Agency has set...

- The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date for November 30, 2021 - Plinabulin and G-CSF combination has the potential to raise the standard of care in CIN prevention for the first time in 30 years NEW YORK, June 01, 2021 (GLOBE NEWSWIRE) ...

NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that management is scheduled to present at the Jefferies Virtual Heal...

BeyondSpring (BYSI) presents data from a Phase 1 study of plinabulin in combination with nivolumab and ipilimumab in 16 patients for the treatment of 2nd and 3rd line small cell lung cancer ((SCLC)) at the American Society of Clinical Oncology ((ASCO)) Annual Meeting on June 4 - 8, ...

- Data from U.S. Phase 1 dose escalation investigator-initiated trial demonstrated favorable safety and tolerability. - Plinabulin, in combination with nivolumab and ipilimumab, shows 46% objective response rate (ORR) in 13 evaluable patients with PD-1/PD-L1 naïve or resistan...

NEW YORK, May 10, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that that CEO Dr. Lan Huang is scheduled to present at the Bank of Am...